Key highlights
07 July 2023 – 1 mins read
LinkedIn
Twitter
Facebook
Primary Biliary Cholangitis (PBC): Looking Beyond the Liver
“Symptom burden is the main issue for the patient.”– Professor Andreas Kremer, Hepatologist of the University of Zurich Hospital
Explore more by category
Showing: 1 – 10 of 80 stories
28 October 2020 – 2 mins read
Liver Cancer Awareness Month – Rethink liver cancer
October is Liver Cancer Awareness Month and this year we are proud to be supporting the European Liver Patients Association (ELPA) with their campaign encouraging everyone to rethink liver cancer by bringing it to the forefront of conversations.
14 October 2020 – 2 mins read
Breast Cancer Awareness Month: raising awareness with inspirational patient stories
The facts and figures around breast cancer bring into focus the importance of raising awareness of the true scale of this globally prevalent disease. Breast cancer is the most common cancer in women1. It comprises of 24% of all cancers…
09 October 2020 – 2 mins read
Using real-world data for better solutions for patients
Innovation to improve patient outcomes doesn’t always resemble the scenes in the movies where the brilliant scientist makes a breakthrough alone in the lab. Sometimes it takes the form of Artificial Intelligence analyzing enormous quantities of data. Sometimes it looks…
02 September 2020 – 2 mins read
Executive Leadership Team Announcement
We are pleased to announce the appointment of Bartek Bednarz, Executive Vice President Global Product & Portfolio Strategy and Patrice Zagame, Executive Vice President, Specialty Care International to the Executive Leadership Team (ELT), effective immediately.
01 July 2020 – 1 mins read
David Loew joins Ipsen as CEO
We are delighted to welcome David Loew as the new CEO of Ipsen. A seasoned professional, David’s career has spanned nearly thirty years in the pharmaceutical industry in such companies as Roche and Sanofi. His leadership skills and experience in…
‘Get men talking’: breaking the silence around prostate cancer
Tim Batchelor, Ipsen’s Head of Global Commercial Learning & Development, candidly shares his experience of living with prostate cancer. At the age of 48, Tim was confronted with a prostate cancer diagnosis. His early detection proved pivotal, leading to successful…
Primary Biliary Cholangitis: The Power of Patient Reported Outcomes
“The important thing with PBC is to take a holistic view of it, and think ‘What are the problems we are trying to solve? The first is the risk of progression to cirrhosis, and the other is symptoms and quality…
Ipsen sponsors 5 elite athletes on their journeys to the 2024 Paralympics
Starting now and throughout 2024, Ipsen is sponsoring five talented, elite athletes on their journeys toward the 2024 Paralympic Games.
The Liver Meeting 2023: Innovating for people living with rare liver diseases
Jennifer Schranz (Ipsen’s Global Head of Rare Diseases) attended The Liver Meeting from November 10-14, sharing key insights from her time onsite and explaining why scientific congresses are vital in helping advance innovation for patients.
Ipsen’s mission to accelerate innovation in oncology
The outputs from the European Society of Medical Oncology (ESMO) Congress this year encompassed several important new data announcements, highlighting key advances in the development of therapies for people living with cancer. However, cancer remains a formidable global health challenge,…
Examining the European Pharma legislation: EFPIA publishes the Dolon Report
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has commissioned Dolon to develop a report to assess the impact of the proposed European Commission pharma legislation. The Dolon Report, published on 6 November, has projected that the proposed legislation…
Capital Markets Day 2023
Ipsen plans to host a capital-markets day, starting at 12.30 pm GMT on 7 December 2023, at The Brewery, London. In-person attendance is by invitation only.
Ipsen stands together to make innovation in rare disease happen
Developing innovation for people living with rare diseases is uniquely challenging. It requires all the different pieces of the puzzle– clinical viability, economic viability and the policy environment— to come together before innovation can reach patients.
Innovating for people living with primary biliary cholangitis
At Ipsen we have been focused on developing new and innovative treatments for rare diseases for many years in endocrinology, rare bone disease and more recently in rare liver disease. This focus continues to be a core part of our…
Rising to the challenge, life after stroke
Globally, stroke is the 2nd leading cause of death worldwide, in addition to being the 3rd leading cause of combined death and disability across the world, with approximately 1 in 4 people over the age of 25 expected to experience…